IBM’s Two-Front Battle: A Quantum Bet to Offset a Mainframe Freefall
Published on 07/26/2026 at 08:02 | Redaktion boerse-global.de
On the surface, IBM’s stock managed a modest recovery on Friday, climbing 3.74 percent to close at €188.38. But that bounce, coming just two days after the shares touched a fresh 52-week low of €175.14, feels less like a turnaround and more like a collective exhale. Year-to-date, the stock remains down 27.52 percent, and the scars from a brutal second-quarter earnings report are far from healed.
The numbers tell a story of a company pulling in two directions at once. Revenue inched up 1 percent to $17.2 billion in the second quarter of 2026, but beneath that headline lurks a deepening fracture. The zSystems mainframe division—once a bellwether for IBM’s hardware prowess—collapsed by 42 percent, dragging the entire infrastructure segment down 7 percent. Management has taken to calling this a “air pocket” phenomenon, but the scale of the drop raises questions about whether it’s a temporary void or a structural shift.
Perhaps more troubling is the slowdown in software, the segment that was supposed to be IBM’s escape route from hardware dependency. After posting 11 percent growth in the first quarter, software expansion halved to just 5 percent in the second. That deceleration forced CFO James Kavanaugh to trim the full-year revenue forecast to 4–5 percent growth at constant currencies, down from an earlier projection of over 5 percent. For a company whose entire investment thesis rests on software acceleration, that revision is a flashing yellow light.
A Quantum Bet to Change the Narrative
IBM isn’t waiting for the market to decide its fate. On July 23, the company signed a binding agreement to acquire HRL Laboratories, a quantum research institute previously co-owned by Boeing and General Motors. The deal is expected to close by the end of the third quarter, pending regulatory approvals. The timing is deliberate: HRL brings silicon-spin qubit expertise that complements IBM’s existing superconducting quantum roadmap, and it pairs neatly with the Anderon quantum wafer foundry launched in May.
Should investors sell immediately? Or is it worth buying IBM?
The acquisition gives IBM a dual-pronged strategy toward fault-tolerant quantum systems. Boeing and GM have signaled they will continue collaborating with IBM on quantum applications post-closing—a tangible sign that major customers remain engaged. For bulls, this is the foundation of a re-rating story: if software momentum holds and quantum revenue begins to materialize, IBM could shed its legacy hardware label and be valued as a technology pioneer.
The Bear Case: A Race Against Time
Skeptics counter that the erosion in core businesses is outpacing the build-out of new ones. The 42 percent mainframe plunge suggests enterprises are reallocating IT budgets away from legacy infrastructure at an accelerating clip. Meanwhile, consulting remains stagnant, and specialized competitors appear to be capturing a growing share of AI-related spending. The heavy investment in quantum research and the Anderon foundry could weigh on cash flow for years before these technologies become commercially viable.
Institutional investors are showing signs of impatience. Unisphere Establishment trimmed its IBM position by 13.1 percent in the first quarter, while the Bank of Nova Scotia cut by 29.2 percent. That’s a clear signal that at least some large holders are unwilling to wait out the long lead time to meaningful quantum and AI revenue.
Cost-Cutting as a Bridge
Kavanaugh is trying to buy time. IBM has raised its annual cost-savings target to over $5.5 billion, arguing that current friction stems from temporary supply constraints tied to AI infrastructure buildout. The message is that the integrated business model is working, even if the quarterly optics are messy. Whether that convinces the market depends on which lens you use.
Retail investors remain divided. Some are leaning on CEO commentary about quantum computing breakthroughs, including recent advances in quantum-assisted supercomputers for fusion energy research. Others are wary of AI-driven disruption, particularly after concerns about the impact of generative AI on legacy codebases like COBOL triggered sharp sell-offs earlier this year. Adding to the uncertainty, investigations into possible securities fraud following the earnings miss have introduced a legal overhang.
IBM at a turning point? This analysis reveals what investors need to know now.
Charting a Path Forward
Technically, the stock is bruised but not broken. It trades 17.61 percent below its 50-day moving average of €228.64 and 19.44 percent below the 200-day average of €233.84—clear evidence of the recent selling pressure. The relative strength index at 35.5 is approaching oversold territory, which may explain Friday’s buying near the year’s low. The average analyst price target of €231.06 implies 22.7 percent upside from current levels, but that depends on the mainframe “air pocket” proving temporary rather than permanent.
The key support level to watch is the 52-week low of €175.14. As long as that holds, the stock is likely to consolidate as the market digests the lowered growth forecast. The next major catalyst is the HRL acquisition closing by the end of the third quarter, along with any regulatory updates. Applied Digital’s earnings on July 27 could also sway sentiment around AI infrastructure spending, indirectly affecting IBM’s valuation.
With annualized 30-day volatility hovering near 85 percent, further sharp swings are all but guaranteed. The wide gap to the 52-week high of €292.85 may attract value-oriented institutional buyers—similar to the Healthcare of Ontario Pension Plan, which nearly doubled its position earlier this year. But until software growth re-accelerates, IBM remains a bet on a turnaround that has yet to prove itself.
Ad
IBM Stock: New Analysis - 26 July
Fresh IBM information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
